Supplementary Data from The Next-Generation Oral Selective Estrogen Receptor Degrader Camizestrant (AZD9833) Suppresses ER+ Breast Cancer Growth and Overcomes Endocrine and CDK4/6 Inhibitor Resistance
Authors:
- Mandy LawsonMLMandy Lawson
- Natalie CuretonNCNatalie Cureton
- Susana RosSRSusana Ros
- Azadeh Cheraghchi-BashiACAzadeh Cheraghchi-Bashi
- Jelena UrosevicJUJelena Urosevic
- Sophie D'ARcySDSophie D'ARcy
- Oona DelpuechODOona Delpuech
- Michelle DuPontMDMichelle DuPont
- David I. FisherDFDavid I. Fisher
- Eric T. GanglEGEric T. Gangl
- Hilary LewisHLHilary Lewis
- Dawn TruemanDTDawn Trueman
Open Access
- 8 March 2024
- other
- Published by American Association for Cancer Research (AACR)
Abstract
Supplementary file containing all supplementary tables, text and figuresKeywords
This publication has 4 references indexed in Scilit:
- Discovery of AZD9833, a Potent and Orally Bioavailable Selective Estrogen Receptor Degrader and AntagonistJournal of Medicinal Chemistry, 2020
- Therapeutic Ligands Antagonize Estrogen Receptor Function by Impairing Its MobilityCell, 2019
- Activating ESR1 Mutations Differentially Affect the Efficacy of ER AntagonistsCancer Discovery, 2017
- GSVA: gene set variation analysis for microarray and RNA-Seq dataBMC Bioinformatics, 2013